The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 11032 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease.. Expert Opin Ther Targets. 17(7), 861-2.
Athyros, V. G., Katsiki N., Karagiannis A., & Radak D. (2014).  Effect of Statins on rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy.. Curr Vasc Pharmacol.
Athyros, V. G., Karagiannis A., Kakafika A., Elisaf M., & Mikhailidis D. P. (2007).  Statins and renal function. Is the compound and dose making a difference?. Nephrol Dial Transplant. 22(3), 963-4; author reply 964.
Athyros, V. G., & Mikhailidis D. P. (2016).  High incidence of metabolic syndrome further increases cardiovascular risk in patients with type 2 diabetes. Implications for everyday practice.. J Diabetes Complications. 30(1), 9-11.
Athyros, V. G., & Wierzbicki A. S. (2014).  Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low.. Curr Med Res Opin. 30(1), 57-8.
Athyros, V. G., Tziomalos K., Karagiannis A., Anagnostis P., & Mikhailidis D. P. (2010).  Should adipokines be considered in the choice of the treatment of obesity-related health problems?. Curr Drug Targets. 11(1), 122-35.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Cold temperature and cardiovascular mortality.. Circ J. 77(11), 2846.
Athyros, V. G., Kakafika A. I., Wierzbicki A. S., Karagiannis A., & Mikhailidis D. P. (2009).  Targeting triglycerides in secondary prevention: should we bother?. Int J Clin Pract. 63(1), 15-8.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Lipid-lowering agents and new onset diabetes mellitus.. Expert Opin Pharmacother. 11(12), 1965-70.
Athyros, V. G., Katsiki N., & Karagiannis A. (2014).  Treating heart failure with preserved ejection fraction: statins could make the difference.. Angiology. 65(4), 328-9.
Athyros, V. G., Tziomalos K., Katsiki N., & Mikhailidis D. P. (2014).  Novel data on the pathogenesis of atherosclerosis, treatment targets, and new therapeutic interventions in lipid-related cardiovascular risk factors.. Curr Pharm Des. 20(40), 6215-9.
Athyros, V. G., Tziomalos K., Doumas M., Sfikas G., & Karagiannis A. (2017).  The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins.. Curr Pharm Des. 23(10), 1477-1483.
Athyros, V. G., Liberopoulos E. N., Mikhailidis D. P., Papageorgiou A. A., Ganotakis E. S., Tziomalos K., et al. (2007).  Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, CHD, stroke, and peripheral arterial disease in a Mediterranean cohort.. Angiology. 58(6), 689-97.
Athyros, V. G., Mikhailidis D. P., Papageorgiou A. A., Didangelos T. P., Peletidou A., Kleta D., et al. (2005).  Targeting vascular risk in patients with metabolic syndrome but without diabetes.. Metabolism. 54(8), 1065-74.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Paraskevas K. I., Tziomalos K., Anagnostis P., et al. (2008).  Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study.. Curr Med Res Opin. 24(6), 1593-9.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2012).  Editorial: should chronic kidney disease be considered as a coronary heart disease equivalent?. Curr Vasc Pharmacol. 10(3), 374-7.
Athyros, V. G., Mikhailidis D. P., Kakafika A. I., Tziomalos K., & Karagiannis A. (2007).  Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?. Expert Opin Pharmacother. 8(5), 529-35.
Athyros, V. G., Mitsiou E. K., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?. Curr Vasc Pharmacol. 8(1), 1-4.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2015).  Short-, mid-, and long-term benefits of peri-procedural high-intensity statin administration in patients undergoing percutaneous coronary intervention.. Curr Med Res Opin. 31(2), 191-5.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. Expert Opin Investig Drugs. 17(12), 1777-9.
Athyros, V. G., Katsiki N., Karagiannis A., & Mikhailidis D. P. (2014).  The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!. Curr Med Res Opin. 30(9), 1701-5.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Statin-fibrate combination for mixed dyslipidaemia: a limited option?. Curr Med Res Opin. 26(9), 2137-40.
Athyros, V. G., Kakafika A. I., Papageorgiou A. A., Tziomalos K., Skaperdas A., Pagourelias E., et al. (2007).  Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients.. Lipids. 42(11), 999-1009.
Athyros, V. G., Tziomalos K., Karagiannis A., Wierzbicki A. S., & Mikhailidis D. P. (2010).  Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. Curr Opin Cardiol. 25(4), 406-10.
Athyros, V. G., Tziomalos K., & Karagiannis A. (2015).  Editorial: Statins or Fibrates for the Primary Prevention of Stroke in the Elderly. Faith Makes Some Things Achievable, But Not AII.. Curr Vasc Pharmacol. 13(6), 696-8.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.